.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
AstraZeneca
Federal Trade Commission
Fish and Richardson
Covington
Baxter
McKinsey
Boehringer Ingelheim
Farmers Insurance
Argus Health

Generated: December 12, 2017

DrugPatentWatch Database Preview

Allopurinol; lesinurad - Generic Drug Details

« Back to Dashboard

What are the generic sources for allopurinol; lesinurad and what is the scope of allopurinol; lesinurad patent protection?

Allopurinol; lesinurad
is the generic ingredient in one branded drug marketed by Ironwood Pharms Inc and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Allopurinol; lesinurad has one hundred and seventy-three patent family members in thirty-eight countries and eleven supplementary protection certificates in nine countries.

There are twenty-one drug master file entries for allopurinol; lesinurad. One supplier is listed for this compound.

Summary for allopurinol; lesinurad

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-001Aug 18, 2017RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-001Aug 18, 2017RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-002Aug 18, 2017RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-001Aug 18, 2017RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-002Aug 18, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-002Aug 18, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-001Aug 18, 2017RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-002Aug 18, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-001Aug 18, 2017RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-002Aug 18, 2017RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: allopurinol; lesinurad

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,552,043N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors► Subscribe
8,344,012Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
7,435,752N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors► Subscribe
8,946,273S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase► Subscribe
8,633,232Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
8,173,690Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
8,481,581S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase► Subscribe
8,106,205N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]p-amino benzoic acids as HIV reverse transcriptase inhibitors► Subscribe
8,193,234Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
8,252,828S-triazolyl .alpha.-mercapto acetanilides as inhibitors of HIV reverse transcriptase► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: allopurinol; lesinurad

Country Document Number Estimated Expiration
Japan5918327► Subscribe
South Korea20090111357► Subscribe
European Patent Office2582683► Subscribe
Mexico2010005776► Subscribe
Japan5099794► Subscribe
Eurasian Patent Organization201000897► Subscribe
Hong Kong1172326► Subscribe
South Korea20100085195► Subscribe
EcuadorSP077322► Subscribe
CroatiaP20170187► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALLOPURINOL; LESINURAD

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0031France► SubscribePRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
2016024Lithuania► SubscribePRODUCT NAME: LESINURADAS; REGISTRATION NO/DATE: EU/1/15/1080 20160218
0160027 00203Estonia► SubscribePRODUCT NAME: LESINURAAD;REG NO/DATE: EU/1/15/1080 22.02.2016
169Luxembourg► SubscribePRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222
0825Netherlands► SubscribePRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
2016 00034Denmark► SubscribePRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
/2016Austria► SubscribePRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222
2016000060Germany► SubscribePRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 20160218
2016024,C2135608Lithuania► SubscribePRODUCT NAME: LESINURADAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/1080 20160218
2016 00034Denmark► SubscribePRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
QuintilesIMS
Moodys
US Army
AstraZeneca
Federal Trade Commission
Cantor Fitzgerald
Novartis
Fish and Richardson
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot